AVN 72.11 Increased By ▲ 0.69 (0.97%)
BOP 9.04 Increased By ▲ 0.02 (0.22%)
CHCC 136.40 Increased By ▲ 0.23 (0.17%)
DCL 9.75 Increased By ▲ 0.08 (0.83%)
DGKC 106.74 Decreased By ▼ -0.06 (-0.06%)
EFERT 61.40 Decreased By ▼ -0.09 (-0.15%)
EPCL 45.64 Increased By ▲ 0.34 (0.75%)
FCCL 21.46 Decreased By ▼ -0.02 (-0.09%)
FFL 15.10 No Change ▼ 0.00 (0%)
HASCOL 15.26 Increased By ▲ 0.10 (0.66%)
HBL 129.98 Decreased By ▼ -0.13 (-0.1%)
HUBC 84.54 Decreased By ▼ -0.01 (-0.01%)
HUMNL 6.04 No Change ▼ 0.00 (0%)
JSCL 28.37 Decreased By ▼ -0.13 (-0.46%)
KAPCO 28.62 Increased By ▲ 0.02 (0.07%)
KEL 3.69 Increased By ▲ 0.03 (0.82%)
LOTCHEM 13.20 Increased By ▲ 0.04 (0.3%)
MLCF 40.95 Decreased By ▼ -0.02 (-0.05%)
OGDC 102.95 Increased By ▲ 0.05 (0.05%)
PAEL 34.70 No Change ▼ 0.00 (0%)
PIBTL 12.83 Decreased By ▼ -0.02 (-0.16%)
PIOC 95.43 No Change ▼ 0.00 (0%)
POWER 9.70 No Change ▼ 0.00 (0%)
PPL 92.83 Increased By ▲ 0.01 (0.01%)
PSO 206.80 Increased By ▲ 0.04 (0.02%)
SNGP 44.23 Decreased By ▼ -0.07 (-0.16%)
STPL 16.00 Decreased By ▼ -0.25 (-1.54%)
TRG 72.95 Decreased By ▼ -0.36 (-0.49%)
UNITY 27.36 Increased By ▲ 0.05 (0.18%)
WTL 1.10 Increased By ▲ 0.05 (4.76%)
BR100 4,399 Increased By ▲ 24.17 (0.55%)
BR30 22,249 Increased By ▲ 134.76 (0.61%)
KSE100 42,207 Increased By ▲ 159.28 (0.38%)
KSE30 17,683 Increased By ▲ 17.86 (0.1%)
Business & Finance

Novartis acquires manufacturing facility to produce medicines in Pakistan

  • “This investment signifies that the regulatory reforms and competitive local landscape is being recognized as an opportunity by investors," said the Advisor.
19 Oct 2020

Novartis, a Switzerland based Multinational has acquired a manufacturing facility to produce medicines locally.

Novartis with a multi-decade presence in Pakistan and has an expansion plan that will bring an investment of about USD 20 million, informed Advisor to Prime Minister on Trade and Investment Abdul Razak Dawood on Monday.

“This investment signifies that the regulatory reforms and competitive local landscape is being recognized as an opportunity by investors," said the Advisor.

Dawood was of the view that the latest acquisition shows the confidence of international companies to invest in the future of the Pakistani pharmaceutical industry and highlights the realization of increased ease in doing business in Pakistan.

It is pertinent to mention, that Novartis maintained strong operational performance in Q1 FY 2020, its net sales from continuing operations grew 13 percent with double digits growth in Innovative Medicines and Sandoz.

Key growth drivers include Entresto USD 569 million (+62pc), Zolgensma USD 170 million, Cosentyx USD 930 million (+19pc), Kisqali USD 161 million (+82 pc) and Piqray USD 74 million, Biopharmaceuticals grew 31pc to USD 450 million, with strong growth in Europe.